Rationale for neoadjuvant immunotherapy in head and neck squamous cell carcinoma

In patients with locoregionally advanced squamous cell carcinoma of the head and neck (SCCHN), current treatment guidelines recommend surgery with post-operative adjuvant therapy or definitive chemoradiotherapy (CRT) as standard of care. Despite these intensive multimodality treatments, recurrence of disease persists asa key cause for treatment failure. Recurrent disease is especially problematic in human papillomavirus (HPV)-unrelated SCCHN.

http://ift.tt/2wwm6Di